Search research articles
Contact Us
Filters
Showing results (91-100 of 212) with videos related to
Page
of 22
Sort By:
Blood
|
May 10, 2011
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605
Mikkael A Sekeres, Holly Gundacker, Jeffrey Lancet, et al.
Leukemia Research
|
February 7, 2018
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)
Anjali S Advani, Hongli Li, Laura C Michaelis, et al.
Cancer
|
June 10, 2011
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
Lewis R Silverman, Pierre Fenaux, Ghulam J Mufti, et al.
Plos One
|
December 4, 2014
Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors
Kathy L McGraw, Ashley A Basiorka, Joseph O Johnson, et al.
Leukemia & Lymphoma
|
June 15, 2012
Unusual concurrence of T-cell large granular lymphocytic leukemia with Franklin disease (gamma heavy chain disease) manifested with massive splenomegaly
Ling Zhang, Eduardo M Sotomayor, Peter R Papenhausen, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 5, 2017
The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval
Andrew T Kuykendall, Chetasi Talati, Najla Al Ali, et al.
Leukemia
|
July 15, 2020
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
Valeria Santini, Pierre Fenaux, Aristoteles Giagounidis, et al.
Haematologica
|
April 16, 2016
Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia
Kathy L McGraw, Johnny Nguyen, Rami S Komrokji, et al.
Leukemia Research
|
January 21, 2014
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure
Michael V Jaglal, Vu H Duong, Celeste M Bello, et al.
Blood Cancer Journal
|
October 7, 2018
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
Mikkael A Sekeres, Arlene S Swern, Aristoteles Giagounidis, et al.
Page
of 22
Search research articles
Search
Showing results (91-100 of 212) with videos related to
Sort By:
Page
of 22
Blood
|
May 10, 2011
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605
Mikkael A Sekeres, Holly Gundacker, Jeffrey Lancet, et al.
Leukemia Research
|
February 7, 2018
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)
Anjali S Advani, Hongli Li, Laura C Michaelis, et al.
Cancer
|
June 10, 2011
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
Lewis R Silverman, Pierre Fenaux, Ghulam J Mufti, et al.
Plos One
|
December 4, 2014
Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors
Kathy L McGraw, Ashley A Basiorka, Joseph O Johnson, et al.
Leukemia & Lymphoma
|
June 15, 2012
Unusual concurrence of T-cell large granular lymphocytic leukemia with Franklin disease (gamma heavy chain disease) manifested with massive splenomegaly
Ling Zhang, Eduardo M Sotomayor, Peter R Papenhausen, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 5, 2017
The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval
Andrew T Kuykendall, Chetasi Talati, Najla Al Ali, et al.
Leukemia
|
July 15, 2020
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
Valeria Santini, Pierre Fenaux, Aristoteles Giagounidis, et al.
Haematologica
|
April 16, 2016
Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia
Kathy L McGraw, Johnny Nguyen, Rami S Komrokji, et al.
Leukemia Research
|
January 21, 2014
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure
Michael V Jaglal, Vu H Duong, Celeste M Bello, et al.
Blood Cancer Journal
|
October 7, 2018
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
Mikkael A Sekeres, Arlene S Swern, Aristoteles Giagounidis, et al.
Page
of 22